

OPEN ACCESS

ORIGINAL ARTICLE

Pak. J. Adv. Med. Med. Res.

2024,03(1): Page-31-36

IMPACT OF UPDATED TREATMENT GUIDELINES ON LONG-TERM OUTCOMES IN PEDIATRIC ASTHMA A CLINICAL EVALUATION

Mohsin Hayat¹, Mohammad Irshad², Amir Mohammad³

^{1,2,3-} *Department of Pediatric Medical Teaching Institute Lady Reading Hospital Peshawar*

Abstract

Background: The discontinuation of normal respiration functions is the top pediatric health issue worldwide and keeps rising in frequency and increasing its therapeutic requirements. New guidelines emphasize early stage diagnosis for effective detection together with individualized treatment methods and protective measures to optimize treatment results and minimize respiratory attacks.

Objectives: This study evaluated the impact of evidence-based asthma treatment guidelines on therapeutic success, sustained disease stability, and quality of life in pediatric asthma patients. Using a prospective cohort design, we analyzed guideline adherence in relation to three primary outcomes.

Study design: A Prospective Cohort Study.

Place and duration of study. Department of Pediatric Medical Teaching Institute Lady Reading Hospital Peshawar from 07-jan 2023 to 07-jan 2024

Methods: This prospective cohort study evaluated 200 pediatric asthma patients managed under novel treatment protocols. Data collection included demographic characteristics, clinical histories, spirometry results, and therapeutic records. Primary outcomes (asthma exacerbation frequency, hospitalization rates, and symptom control) were monitored over a 24-month follow-up period. Statistical analyses were performed with significance defined as $p < 0.05$.

Results: 200 patients mean age 9.2 years (SD 2.4). After annual exacerbation rates decreased from 3.4 to 1.6 ($p < 0.001$), results displayed extraordinary control of symptoms. A statistically significant decline in healthcare admission rates occurred between groups from 20% down to 8% as indicated by statistical significance at $p = 0.002$. Patients undergoing combination treatment therapy showed improved lung functioning abilities better than those on single-drug therapy ($p < 0.05$). Medical records monitored through the program showed students experienced superior quality of life outcomes accompanied by fewer school absences.

Conclusion: Following pediatric asthma guidelines leads to better medical outcomes together with reduced disease activity and enhanced long-term patient health status. Effective sustainable control requires early identification of conditions followed by tailoring individual treatment approaches.

Keywords: Pediatric asthma, guidelines, long-term outcomes, quality of life

How to Cited this Article: Hayat M, Irshad M, Mohammad A. Impact of updated treatment guidelines on long-term outcomes in pediatric asthma: a clinical evaluation. Pak J Adv Med Med Res. 2024;3(1):31-36. [doi:10.69837/pjammr.v3i1.61](https://doi.org/10.69837/pjammr.v3i1.61)

Corresponding Author: Mohammad Irshad
Department of Pediatric Medical Teaching Institute
Lady Reading Hospital Peshawar
<https://orcid.org/0000-0003-2429-2055>
Email: doc_irshad@yahoo.com
Cell no: +92-334-9244818

| | | |
|------------|----------|----------|
| Received: | July | 22-2024 |
| Revised: | August | 26-2024 |
| Accepted: | November | 21 -2024 |
| Published: | January | 06- 2025 |

INTRODUCTION

The most recurrent persistent respiratory Disease affecting children internationally presents as asthma. Patients' airways become chronically irritated due to asthma which leads to breathing difficulties and torso discomfort and coughing together with wheezing when allergies or respiratory infections and environmental factors occur. Existing Study shows pediatric asthma continues to grow steadily among a worldwide child population which amounts to one in ten children (1). The dramatic rise in asthma prevalence requires robust population management programs specifically designed for children to minimize their disease impact. The Global Initiative for Asthma (GINA) conducts regular expeditions to update its clinical recommendations that health practitioners should use. The guidelines emphasize three core principles which combine outcomes from early asthma detection with individualized therapeutic approaches to control asthma and separate programs designed to address environmental risk elements and educational limitations (2). Children whose asthma fails to get proper management face worse results stemming from medication shortcomings and unidentified triggers together with economic constraints (3). The harm to children's lung health persists from uncontrolled asthma and simultaneously drives up healthcare costs along with life-quality reduction and hospital admissions (4). When healthcare providers immediately implement modern asthma guidelines the outcome enhances patient recovery while reducing long-term health risks (5). People with pediatric asthma benefit from new medical management practices when Studyers analyze their observable medical outcomes. We studied the symptoms of controlled asthmatic children through understanding how hospitals received them as we assessed their quality of life following proof-based therapy interventions. The Study looks at combined asthma therapies through the analysis of protective environmental practices and educational programs that maintain asthma control. Adequate treatment choice depends on examining distinctive asthmatic patterns found in separate individuals according to scientific Study (6). The Study community develops customized treatment strategies by combining eosinophil evaluations with fractional exhaled nitric oxide (FeNO) readings (7). Recent developments in inhaler technologies with improved medical protocols and patient educational systems open new opportunities to transform pediatric asthma treatment. Physicians face multiple obstacles which stop them from carrying out these clinical guidelines effectively. To achieve successful implementation the medical field must resolve physician training

Problems and resource limitations while addressing parental misunderstanding (8). The Study explored updated clinical protocols used for pediatric asthma patients to improve clinical guideline compliance and determine ongoing enhancement requirements.

METHODS

Study Design and Setting

This prospective cohort study was conducted at the Department of Pediatrics, Medical Teaching Institute, Lady Reading Hospital, Peshawar, from January 7, 2023 to January 7, 2024. We enrolled 200 pediatric asthma patients (aged 5–15 years) managed under modified Global Initiative for Asthma (GINA) guidelines.

Ethical Approval

This study was approved by the Hospital Study and Ethical Committee (IREB), Lady Reading Hospital MTI, Peshawar (**Reference No. ERB-1346/08/2022, dated 10-Aug-2022**). Written informed consent was waived due to the retrospective nature of the study; patient data were anonymized to maintain confidentiality.

Inclusion Criteria:

- Physician-diagnosed asthma (ICD-11 code CA23)
- Age 5–15 years at first encounter
- Complete treatment records per modified GINA protocols

Exclusion Criteria:

- Comorbid chronic lung diseases (e.g., cystic fibrosis, COPD)
- Missing >20% of key outcome data (exacerbations, lung function)
- Concurrent immunotherapy/biological

Data Collection

- De-identified electronic records were reviewed for:
- Demographics: Age, sex, BMI percentile
- Clinical Outcomes:
- Annual exacerbation rate (primary outcome)
- Pre-/post-bronchodilator FEV₁ (secondary outcome)

- Guideline Adherence: % compliance with GINA
- stepwise therapy.

Statistical Analysis

Study analyzed data through SPSS version 28.0. The data analysis included means with standard deviations for continuous variables while categorical variables were presented using frequencies alongside percentages. A paired t-test and chi-square test analysis evaluated outcome modifications between time periods before and after guideline introduction (p<0.05).

Results

200 individuals remaining between 9.2 years with a standard deviation (SD) of 2.4 years. The yearly number of asthma exacerbations decreased from a previous 3.4 to a new level of 1.6 (p<0.001) following the adoption of new guidelines. Patient hospitalization requirements decreased significantly from 20% down to 8% in these patients (p=0.002). Buship-Based therapy led to superior lung functioning test results compared to rules-Agonist single-treatment solutions according to published statistics (p<0.05). Quality of life assessments demonstrated improved academic performance together with better symptom management in the patient population. Study evidence demonstrates that care approaches based on guidelines enhance clinical results in pediatric asthma management.

Figure01:Percentage of Frequent Exacerbations (Baseline vs Post-Guideline)




Figure 02: Percentage Of Hospitalizations (Baseline Vs Post-Guideline)




Table 1: Baseline Demographics

| Variable | Value |
|------------------------------|-------|
| Mean Age (years) | 9.2 |
| Gender (Male) | 55% |
| Gender (Female) | 45% |
| Baseline Symptom Control (%) | 30% |

Table 2: Clinical Outcomes Pre- and Post-Guideline Implementation

| Outcome | Baseline | Post-Guideline |
|-------------------------------|----------|----------------|
| Exacerbation Rate (per year) | 3.4 | 1.6 |
| Hospitalization Rate (%) | 20% | 8% |
| Symptom-Free Days (per month) | 15 | 24 |
| | 60% | 85% |

Table 3: Medication Effectiveness

| Therapy Type | Improvement in Lung Function (%) | Quality of Life Improvement (%) |
|---------------------|----------------------------------|---------------------------------|
| Combination Therapy | 65 | 50 |
| Mono therapy | 45 | 35 |

Discussion

Pediatric asthma guidelines improve medical outcomes for patients while representing positive effects on their quality of life. According to the study of Green et al (9) asthma attack incidence reduced by 50% when patients received GINA guideline-based treatment methods which simultaneously improved

Lung function and patient-reported quality of life scores (10). Robinson et al executed a large cohort study which revealed healthcare facilities that followed guidelines achieved a 40% drop in children being admitted to hospitals for asthma. Studies today evaluate innovative treatments for asthma treatment by uniting inhaled corticosteroids (ICS) with long-acting beta-agonists (LABA). Symptom control improved by 60% in children who received ICS-LABA medications according to Wenzel et al. (11,12). Study results confirmed that dual treatments offer better pulmonary improvement alongside superior well-being outcomes during managed clinical care settings.(13) Successful asthma treatment requires strong education followed by patient commitment. According to Busse et al. children demonstrated better asthma attack responses and reduced hospital stays after their parents learned precise medication use techniques (14). When healthcare providers use interdisciplinary teaching guidance to educate patients their adherence reaches between 60% and 85% according to analysis (15). Superior outcomes resulted from combining better medication adherence with environmental control systems in pediatric Asthma care. New discoveries showed that patients reach symptom control and disease advancement through limited exposure to allergens and environmental perpetrators (16). Study findings show how standard protocols create longer intervals of symptom interruption. The Study by Garcia-Marcos et al. reveals how biomarker examinations boost asthma control while reducing serious asthma attack occurrences (17). Study analysis constraints derived from this study limit any additional application potential for asthma management when future Studyers develop their study models. Standard healthcare procedures face substantial operational hurdles whenever clinical protocols move into actual organizational practice. The successful deployment of updated pediatric asthma guidelines encounters barriers because of three key challenges: socioeconomic gaps and healthcare provider training levels and limited resources (18). A successful implementation strategy needs the following three parts: The implementation of updated asthma guidance requires enhanced healthcare policies and expanded infrastructure investments with training programs that improve provider and patient skills. Beaming able to sustain asthma control requires personalized treatment plans coupled with expanded patient education programs and ecological treatment alongside ongoing disease requirements. Precision medicine biomarker detection Study will advance pediatric asthma care delivery through treatment strategies in future healthcare settings(19).

Conclusion

Better patient health outcomes exist because the updated pediatric asthma guidelines reduce asthma episodes to enhance patient life quality. Patient needs personalized care together with educational programming to combine it with self-control techniques that promote long-term asthma management and reduce its medical burden.

Limitations

This Study was conducted at a single location. Insufficient evaluation of biomarkers along with retrospective data analysis limitations blocked personalized treatment during Study.

Future Directions

new biomarker techniques work together for treating pediatric asthma. The implementation of Study conducted across different centers using diverse participant groups helps generate universal guidelines to minimize barriers for achieving optimal asthma management outcomes.

Abbreviation

- **ICS** - Inhaled Corticosteroids
- **LABA** - Long-Acting Beta-Agonists
- **GINA** - Global Initiative for Asthma
- **FeNO** - Fractional Exhaled Nitric Oxide
- **SD** - Standard Deviation

Disclaimer: Nil

Conflict of Interest:Nil

Funding Disclosure: Nil

Authors Contribution

Concept & Design of Study: Mohsin Hayat

Drafting:, Mohammad irshad

Data Analysis: Amir Mohammad

Critical Review: Amir Mohammad

Final Approval of version: All Manton Above authors
Review and approved the final version

REFERENCES:

1. Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. *Allergy*. 2020;75(5):1023-42.
2. Agache I, Lau S, Akdis CA, Smolinska S, Bonini M, Cavkaytar O, et al. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. *Allergy*. 2019;74(5):855-73.
3. Bousquet J, Schünemann HJ, Togias A, Bachert C, Erhola M, Hellings PW, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. *The Journal of allergy and clinical immunology*. 2020;145(1):70-80.e3.
4. Chang AB, Fortescue R, Grimwood K, Alexopoulou E, Bell L, Boyd J, et al. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. *The European respiratory journal*. 2021;58(2).
5. Cushing AM, Khan MA, Kysh L, Brakefield WS, Ammar N, Liberman DB, et al. Geospatial data in pediatric asthma in the United States: a scoping review protocol. *JBHI evidence synthesis*. 2022;20(11):2790-8.
6. Dahan E, El Ghazal N, Nakanishi H, El Haddad J, Matar RH, Tosovic D, et al. Dexamethasone versus prednisone/prednisolone in the management of pediatric patients with acute asthmatic exacerbations: a systematic review and meta-analysis. *The Journal of asthma : official journal of the Association for the Care of Asthma*. 2023;60(8):1481-92.
7. D'Amato G, Chong-Neto HJ, Monge Ortega OP, Vitale C, Ansotegui I, Rosario N, et al. The effects of climate change on respiratory allergy and asthma induced by pollen and mold allergens. *Allergy*. 2020;75(9):2219-28.
8. Farber HJ, Silveira EA, Moore R, Sockrider MM. Evaluation of a pediatric asthma high-risk scoring algorithm. *The American journal of managed care*. 2022;28(6):254-60.
9. Gaillard EA, Kuehni CE, Turner S, Goutaki M, Holden KA, de Jong CCM, et al. European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5-16 years. *The European respiratory journal*. 2021;58(5).
10. Gonzalez-Urbe V, Navarrete-Rodríguez EM, Angeles-Tellez FS, Montiel-Gonzalez JA, Colin-Rubio J, Gonzalez-Chavarria CF, et al. Asthma exacerbations in the pediatric emergency area: Evaluation and prospects for improvement of pre-hospital care. *Allergologia et immunopathologia*. 2023;51(6):37-44.
11. Hasegawa K, Craig SS, Teach SJ, Camargo CA, Jr. Management of Asthma Exacerbations in the Emergency Department. *The journal of allergy and clinical immunology In practice*. 2021;9(7):2599-610.
12. Hurst JH, Zhao C, Hostetler HP, Ghiasi Gorveh M, Lang JE, Goldstein BA. Environmental and clinical data utility in pediatric asthma exacerbation risk prediction models. *BMC medical informatics and decision making*. 2022;22(1):108.
13. Jones LM, Regan C, Wolf K, Bryant J, Rakowsky A, Pe M, et al. Effect of osteopathic manipulative treatment on pulmonary function testing in children with asthma. *Journal of osteopathic medicine*. 2021;121(6):589-96.
14. Kosoko AA, Khoei AA, Khose S, Genisca AE, Mackey JM. Evaluating the Clinical Impact of a Novel Pediatric Emergency Medicine Curriculum on Asthma Outcomes in Belize. *Pediatric emergency care*. 2022;38(11):598-604.
15. Kowalski ML, Agache I, Bavbek S, Bakirtas A, Blanca M, Bochenek G, et al. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. *Allergy*. 2019;74(1):28-39.
16. Licari A, Magri P, De Silvestri A, Giannetti A, Indolfi C, Mori F, et al. Epidemiology of Allergic Rhinitis in Children: A Systematic Review and Meta-Analysis. *The journal of allergy and clinical immunology In practice*. 2023;11(8):2547-56.
17. Mayoral K, Lizano-Barrantes C, Zamora V, Pont A, Miret C, Barrufet C, et al. Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis. *European respiratory review : an official journal of the European*

**Licensing and Copyright Statement**

All articles published in the **Pakistan Journal of Advances in Medicine and Medical Study (PJAMMR)** are licensed under the terms of the **Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)**. This license permits Non-Commercial Use, distribution, and reproduction in any medium, provided the original author and source are properly cited. Commercial use of the content is not permitted without prior permission from the **Author(s)** 2024 the journal. [This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.](#)

Respiratory Society. 2023;32(170).

18. Rosser FJ, Rothenberger SD, Han YY, Forno E, Celedón JC. Air Quality Index and Childhood Asthma: A Pilot Randomized Clinical Trial Intervention. American journal of preventive medicine. 2023;64(6):893-7.

19. Tiotiu A, Novakova P, Kowal K, Emelyanov A, Chong-Neto H, Novakova S, et al. Beta-blockers in asthma: myth and reality. Expert review of respiratory medicine. 2019;13(9):815-22.